139 related articles for article (PubMed ID: 38625984)
21. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
[TBL] [Abstract][Full Text] [Related]
22. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
[TBL] [Abstract][Full Text] [Related]
24. Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.
Tai R; Tirumani SH; Tirumani H; Shinagare AB; Hornick JL; Ramaiya NH
Br J Radiol; 2015 Aug; 88(1052):20140861. PubMed ID: 25989696
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
[TBL] [Abstract][Full Text] [Related]
26. A Focused Review of Epstein-Barr Virus Infections and PTLD in Pediatric Transplant Recipients: Guidance From the IPTA and ECIL Guidelines.
Yamada M; L'Huillier AG; Green M
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S31-S38. PubMed ID: 38417085
[TBL] [Abstract][Full Text] [Related]
27. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.
O'Reilly RJ; Prockop S; Oved JH
Front Immunol; 2023; 14():1290059. PubMed ID: 38274824
[TBL] [Abstract][Full Text] [Related]
28. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
29. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
Cytotherapy; 2018 May; 20(5):706-714. PubMed ID: 29580864
[TBL] [Abstract][Full Text] [Related]
30. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review.
Liu JY; Zhang JM; Zhan HS; Sun LY; Wei L
Transpl Int; 2021 Dec; 34(12):2483-2493. PubMed ID: 34510581
[TBL] [Abstract][Full Text] [Related]
31. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
32. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
Jiménez S
Clin J Oncol Nurs; 2015 Feb; 19(1):94-8. PubMed ID: 25689655
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation: A Single Center Experience of 196 Patients Over 30 Years.
Vergote VKJ; Deroose CM; Fieuws S; Laleman W; Sprangers B; Uyttebroeck A; Van Cleemput J; Verhoef G; Vos R; Tousseyn T; Dierickx D
Transpl Int; 2022; 35():10707. PubMed ID: 36589262
[TBL] [Abstract][Full Text] [Related]
36. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
37. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
38. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
[No Abstract] [Full Text] [Related]
39. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
40. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
